David Wallace
Executive Editor
Having previously worked in the European chemicals industry, Dave has been with Generics Bulletin since 2010. Keeping a close eye on deals, corporate strategy and market developments in the off-patent sector, he also brings his background and education in law to bear on industry litigation as well as national legislative and regulatory affairs, with a particular interest in France where he has lived and studied in the past. A regular delegate to generics and biosimilars events and conferences as well as a frequent panel moderator, he maintains close links with industry representatives around the world. He also organizes and judges the annual Global Generics & Biosimilars Awards. In his spare time, he enjoys art and playing the piano.
Latest From David Wallace
Sandoz Follows US Denosumab Filing With European Acceptance
Sandoz has confirmed dual European filings for its denosumab biosimilar rival to Prolia and Xgeva, a few months after it submitted its candidate in the US.
Pharmascience Welcomes Canadian Ruling On Nitrosamines
Pharmascience was among the firms that were named in a class action lawsuit in Canada over the presence of nitrosamine NDMA in ranitidine. Now, the company has welcomed a summary judgement decision by the Supreme Court of British Columbia to dismiss the claims.
Celltrion Bags FDA Approval For High-Concentration Humira Rival
Celltrion has won US FDA approval for its Yuflyma 100mg/ml adalimumab biosimilar, making it the third high-concentration version approved in the US and the ninth Humira rival overall.
Wave Of New Leaders Could Reshape Generics Industry
With a number of top generics and biosimilars firms announcing new leaders over the past few months, the industry could be in for some strategic shifts as new faces take the helm at established off-patent players.
ANI Aims For CGT Top Spot With Two New Launches
ANI Pharmaceuticals has heralded the approval and launch of two new US competitive generic therapies as giving it a joint leadership position in the CGT space.
Alvotech Makes Multiple Moves As It Allies With Advanz For Five European Biosimilars
In a busy week for Alvotech, the firm has announced an expansion of its partnership with Advanz to cover five further European biosimilars, at the same time as revealing two new pipeline assets. Meanwhile, the company has also dropped three products from an existing European partnership with Stada and has also terminated a development deal with BiosanaPharma.